Skip to content
The Kids Research Institute Australia logo

Real world effectiveness of early ensitrelvir treatment in patients with SARS-CoV-2, a retrospective case series

Ensitrelvir, a 3C-like protease inhibitor, received emergency approval in Japan in November 2022 for treating non-hospitalized patients with mild-to-moderate COVID-19. However, confirmation of its real-world clinical effectiveness is limited.

Citation:
Abe S, Wannigama DL, Suzuki Y, …….. Stick SM, Kicic A. Real world effectiveness of early ensitrelvir treatment in patients with SARS-CoV-2, a retrospective case series. New Microbes New Infect. 2024;62.

Keywords:
Allergic rhinitis; asthma; backache; chronic sinusitis; coronavirus 2019; coughing; nose obstruction; retrospective study; sanger sequencing

Abstract:
Ensitrelvir, a 3C-like protease inhibitor, received emergency approval in Japan in November 2022 for treating non-hospitalized patients with mild-to-moderate COVID-19. However, confirmation of its real-world clinical effectiveness is limited.